NASDAQ:DSCI - Derma Sciences Stock Price, Price Target & More

$7.00 0.00 (0.00 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$7.00
Today's Range$6.96 - $7.05
52-Week Range$2.92 - $7.05
Volume57,400 shs
Average Volume719,592 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Derma Sciences (NASDAQ:DSCI)

Derma Sciences logoDerma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive DSCI News and Ratings via Email

Sign-up to receive the latest news and ratings for DSCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNASDAQ:DSCI
CUSIP24982750
Phone+1-609-5144744

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.02%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20.97%
Return on Equity-17.10%
Return on Assets-12.43%

Miscellaneous

Employees263
Outstanding Shares28,340,000

How to Become a New Pot Stock Millionaire

Derma Sciences (NASDAQ:DSCI) Frequently Asked Questions

What is Derma Sciences' stock symbol?

Derma Sciences trades on the NASDAQ under the ticker symbol "DSCI."

How were Derma Sciences' earnings last quarter?

Derma Sciences Inc (NASDAQ:DSCI) posted its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to the consensus estimate of $22.40 million. Derma Sciences had a negative return on equity of 17.10% and a negative net margin of 20.97%. View Derma Sciences' Earnings History.

Who are some of Derma Sciences' key competitors?

Has Derma Sciences been receiving favorable news coverage?

Media headlines about DSCI stock have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Derma Sciences earned a news sentiment score of 0.11 on Accern's scale. They also gave news coverage about the medical instruments supplier an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Derma Sciences?

Shares of DSCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Derma Sciences' stock price today?

One share of DSCI stock can currently be purchased for approximately $7.00.

How can I contact Derma Sciences?

Derma Sciences' mailing address is 214 Carnegie Ctr Ste 300, PRINCETON, NJ 08540-6237, United States. The medical instruments supplier can be reached via phone at +1-609-5144744.


MarketBeat Community Rating for Derma Sciences (DSCI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  188 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Derma Sciences and other stocks. Vote "Outperform" if you believe DSCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSCI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Derma Sciences (NASDAQ:DSCI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AHold
Consensus Rating Score: N/AN/AN/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Derma Sciences (NASDAQ:DSCI) Consensus Price Target History

Price Target History for Derma Sciences (NASDAQ:DSCI)

Derma Sciences (NASDAQ:DSCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2017Roth CapitalDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Derma Sciences (NASDAQ:DSCI) Earnings History and Estimates Chart

Earnings by Quarter for Derma Sciences (NASDAQ:DSCI)

Derma Sciences (NASDAQ DSCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.04)($0.05)$23.90 million$21.80 millionViewListenView Earnings Details
8/9/2016Q216($0.08)$0.08$22.40 million$22.20 millionViewListenView Earnings Details
5/11/2016Q116($0.13)($0.07)$20.60 million$20.20 millionViewListenView Earnings Details
3/16/2016Q4 2015($0.39)($0.12)$20.24 million$20.25 millionViewN/AView Earnings Details
11/9/2015Q315($0.43)($0.35)$22.31 million$22.20 millionViewListenView Earnings Details
8/10/2015Q215($0.43)($0.36)$21.66 million$22.60 millionViewListenView Earnings Details
5/11/2015Q115($0.46)($0.42)$19.89 million$19.50 millionViewListenView Earnings Details
3/12/2015Q414($0.46)($0.37)$22.90 million$22.90 millionViewListenView Earnings Details
11/10/2014Q314($0.43)($0.45)$21.90 million$20.20 millionViewN/AView Earnings Details
8/7/2014Q2($0.46)($0.34)$21.31 million$20.92 millionViewListenView Earnings Details
5/8/2014Q1($0.28)($0.46)$19.79 million$19.80 millionViewListenView Earnings Details
3/14/2014Q4($0.36)($0.31)$21.26 million$20.70 millionViewListenView Earnings Details
11/13/2013Q3($0.44)($0.29)$21.96 million$22.10 millionViewListenView Earnings Details
8/12/2013Q2 2013($0.45)($0.43)$19.95 million$18.10 millionViewListenView Earnings Details
5/16/2013Q1 2013($0.37)($0.38)$19.00 million$18.80 millionViewListenView Earnings Details
4/1/2013Q4 2012($0.31)($0.27)ViewN/AView Earnings Details
11/12/2012Q312($0.37)($0.24)$19.00 million$19.60 millionViewN/AView Earnings Details
8/14/2012Q2 2012($0.23)($0.23)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.16)($0.24)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.11)($0.23)ViewN/AView Earnings Details
11/11/2011Q3 2011($0.11)($0.07)ViewN/AView Earnings Details
8/16/2011Q2 2011($0.09)($0.08)ViewN/AView Earnings Details
5/11/2011Q1 2011$0.01($0.08)ViewN/AView Earnings Details
3/30/2011Q4 2010($0.07)($0.05)ViewN/AView Earnings Details
11/12/2010Q3 2010$0.08($0.08)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.20)($0.14)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.05)ViewN/AView Earnings Details
4/1/2010Q4 2009$0.01ViewN/AView Earnings Details
11/16/2009Q3 2009($0.08)$0.02ViewN/AView Earnings Details
8/17/2009Q2 2009($0.08)($0.11)ViewN/AView Earnings Details
5/18/2009Q1 2009($0.08)($0.15)ViewN/AView Earnings Details
4/1/2009Q4 2008($0.08)($0.11)ViewN/AView Earnings Details
11/17/2008Q3 2008($0.08)($0.14)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.16)($0.26)ViewN/AView Earnings Details
4/1/2008Q4 2007($0.08)($0.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Derma Sciences (NASDAQ:DSCI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Derma Sciences (NASDAQ DSCI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.94%
Institutional Ownership Percentage: 58.89%
Insider Trading History for Derma Sciences (NASDAQ:DSCI)
Insider Trading History for Derma Sciences (NASDAQ:DSCI)

Derma Sciences (NASDAQ DSCI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2015Srini ConjeevaramDirectorBuy1,100$6.50$7,150.00View SEC Filing  
8/14/2015Samuel E NavarroDirectorBuy10,000$6.51$65,100.00View SEC Filing  
8/13/2015Bruce F WessonDirectorBuy10,000$6.58$65,800.00View SEC Filing  
8/13/2015Edward J QuiltyCEOBuy15,000$6.65$99,750.00View SEC Filing  
8/13/2015Robert C ColeInsiderBuy5,000$6.73$33,650.00View SEC Filing  
6/12/2015Brett HewlettDirectorSell12,000$7.17$86,040.00View SEC Filing  
12/15/2014Srini ConjeevaramDirectorSell12,500$8.49$106,125.00View SEC Filing  
12/4/2014C Richard StaffordDirectorSell6,075$8.59$52,184.25View SEC Filing  
11/25/2014C Richard StaffordDirectorSell1,775$8.26$14,661.50View SEC Filing  
11/18/2014C Richard StaffordDirectorSell3,250$8.59$27,917.50View SEC Filing  
11/17/2014C Richard StaffordDirectorSell1,800$8.50$15,300.00View SEC Filing  
11/14/2014C Richard StaffordDirectorSell5,073$8.48$43,019.04View SEC Filing  
9/16/2014Barry WolfensonInsiderBuy3,750$7.99$29,962.50View SEC Filing  
5/19/2014Barry WolfensonInsiderBuy11,250$8.79$98,887.5075,085View SEC Filing  
5/16/2014Edward QuiltyCEOBuy10,000$8.70$87,000.00170,172View SEC Filing  
1/10/2014Ra Capital Management, LlcInsiderSell300,000$11.83$3,549,000.00View SEC Filing  
9/3/2013C Richard StaffordDirectorSell15,000$14.06$210,900.0031,723View SEC Filing  
9/3/2013John YetterCFOSell12,100$14.16$171,336.0046,784View SEC Filing  
5/30/2013William C MartinMajor ShareholderSell95,568$13.68$1,307,370.24View SEC Filing  
4/29/2013Ra Capital Management, LlcMajor ShareholderBuy3,945$11.40$44,973.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Derma Sciences (NASDAQ DSCI) News Headlines

Source:
DateHeadline
Derma Sciences (DSCI) and Fulgent Genetics (FLGT) Head-To-Head SurveyDerma Sciences (DSCI) and Fulgent Genetics (FLGT) Head-To-Head Survey
www.americanbankingnews.com - March 3 at 4:32 PM
Comparing Digirad (DRAD) and Derma Sciences (DSCI)Comparing Digirad (DRAD) and Derma Sciences (DSCI)
www.americanbankingnews.com - January 31 at 5:10 AM
Edap Tms (EDAP) & Derma Sciences (DSCI) Head to Head ComparisonEdap Tms (EDAP) & Derma Sciences (DSCI) Head to Head Comparison
www.americanbankingnews.com - January 4 at 11:28 AM
Comparing Derma Sciences (DSCI) and Mazor Robotics (MZOR)Comparing Derma Sciences (DSCI) and Mazor Robotics (MZOR)
www.americanbankingnews.com - December 19 at 5:26 AM
Derma Sciences (DSCI) versus Luna Innovations (LUNA) Financial AnalysisDerma Sciences (DSCI) versus Luna Innovations (LUNA) Financial Analysis
www.americanbankingnews.com - December 19 at 3:16 AM
Cogentix Medical (CGNT) versus Derma Sciences (DSCI) Head-To-Head ContrastCogentix Medical (CGNT) versus Derma Sciences (DSCI) Head-To-Head Contrast
www.americanbankingnews.com - November 3 at 3:18 AM
Critical Comparison: Derma Sciences (DSCI) & Its CompetitorsCritical Comparison: Derma Sciences (DSCI) & Its Competitors
www.americanbankingnews.com - October 10 at 4:28 AM
Wednesday’s Top Biopharma MoversWednesday’s Top Biopharma Movers
finance.yahoo.com - October 5 at 10:09 AM
Derma Sciences Buys MEDIHONEY® Brand From Long-Term PartnerDerma Sciences Buys MEDIHONEY® Brand From Long-Term Partner
finance.yahoo.com - October 5 at 10:09 AM
Blog Coverage Integra Set to Acquire Derma Sciences; Announced Outlook 2017Blog Coverage Integra Set to Acquire Derma Sciences; Announced Outlook 2017
finance.yahoo.com - October 5 at 10:09 AM
Company News for January 12, 2017Company News for January 12, 2017
finance.yahoo.com - October 5 at 10:09 AM
DERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Integra LifeSciences Holdings Corporation May be Unfair to ShareholdersDERMA SCIENCES, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Integra LifeSciences Holdings Corporation May be Unfair to Shareholders
finance.yahoo.com - October 5 at 10:09 AM
Integra LifeSciences Buys Derma Sciences for $204MIntegra LifeSciences Buys Derma Sciences for $204M
finance.yahoo.com - October 5 at 10:09 AM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Investors To Contact The Firm For Additional InformationSHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Investors To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 10:09 AM
DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI) Over the Proposed Sale of the Company to Integra LifeSciences Holdings CorporationDERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI) Over the Proposed Sale of the Company to Integra LifeSciences Holdings Corporation
finance.yahoo.com - October 5 at 10:09 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders -- DSCISHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders -- DSCI
finance.yahoo.com - October 5 at 10:09 AM
Harwood Feffer LLP Announces Investigation of Derma Sciences Inc.Harwood Feffer LLP Announces Investigation of Derma Sciences Inc.
finance.yahoo.com - October 5 at 10:09 AM
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Shareholders To Contact The Firm For Additional InformationINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And Encourages Shareholders To Contact The Firm For Additional Information
finance.yahoo.com - October 5 at 10:09 AM
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Derma Sciences, Inc. - DSCISHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Derma Sciences, Inc. - DSCI
finance.yahoo.com - October 5 at 10:09 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to ShareholdersINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is Fair to Shareholders
finance.yahoo.com - October 5 at 10:09 AM
Why One Analyst Sees Almost 40% Upside in Integra LifeSciencesWhy One Analyst Sees Almost 40% Upside in Integra LifeSciences
finance.yahoo.com - October 5 at 10:09 AM
PerkinElmer (PKI) & Derma Sciences (DSCI) Critical ReviewPerkinElmer (PKI) & Derma Sciences (DSCI) Critical Review
www.americanbankingnews.com - September 24 at 12:20 AM
Dextera Surgical (DXTR) & Derma Sciences (DSCI) Head to Head ComparisonDextera Surgical (DXTR) & Derma Sciences (DSCI) Head to Head Comparison
www.americanbankingnews.com - September 14 at 12:28 PM
Comparing Derma Sciences (DSCI) and its CompetitorsComparing Derma Sciences (DSCI) and its Competitors
www.americanbankingnews.com - September 11 at 4:22 AM
Reviewing Derma Sciences (DSCI) & ViewRay (VRAY)Reviewing Derma Sciences (DSCI) & ViewRay (VRAY)
www.americanbankingnews.com - September 3 at 2:12 AM
DERMA SCIENCES, INC. Files SEC form 8-K/A, Financial Statements and ExhibitsDERMA SCIENCES, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
biz.yahoo.com - March 7 at 11:56 AM
DERMA SCIENCES, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or FDERMA SCIENCES, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or F
biz.yahoo.com - February 24 at 11:51 AM
Integra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger Promptly - StreetInsider.comIntegra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger Promptly - StreetInsider.com
www.streetinsider.com - February 23 at 9:48 PM
Integra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger PromptlyIntegra LifeSciences (IART) Says Tender Offer for Derma (DSCI) Expired; to Effect Merger Promptly
www.streetinsider.com - February 23 at 4:48 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is ...INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Derma Sciences, Inc. to Integra LifeSciences Holdings Corporation for $7 Per Share is ...
www.businesswire.com - January 27 at 6:27 PM
Integra LifeSciences Commences Previously Announced Cash Tender Offer to Acquire Derma Sciences, Inc. - GlobeNewswire (press release)Integra LifeSciences Commences Previously Announced Cash Tender Offer to Acquire Derma Sciences, Inc. - GlobeNewswire (press release)
globenewswire.com - January 26 at 6:05 PM
DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal OfficersDERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 25 at 6:00 PM
DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal OfficersDERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - January 25 at 6:00 PM
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And ... - Business Wire (press release)INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc. And ... - Business Wire (press release)
www.businesswire.com - January 17 at 10:41 PM
DERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial StatemenDERMA SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - January 17 at 5:40 PM
DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI ... - PR Newswire (press release)DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI ... - PR Newswire (press release)
www.prnewswire.com - January 15 at 4:40 PM
Integra LifeSciences (IART) to Acquire Derma Sciences (DSCI) for $7/Share, or 40% PremiumIntegra LifeSciences (IART) to Acquire Derma Sciences (DSCI) for $7/Share, or 40% Premium
www.streetinsider.com - January 13 at 10:36 PM
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc ... - Business Wire (press release)SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Derma Sciences, Inc ... - Business Wire (press release)
www.businesswire.com - January 12 at 10:35 PM
Integra Buys Derma Sciences for $204M (IART, DSCI)Integra Buys Derma Sciences for $204M (IART, DSCI)
www.investopedia.com - January 12 at 5:15 PM

SEC Filings

Derma Sciences (NASDAQ:DSCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Derma Sciences (NASDAQ:DSCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Derma Sciences (NASDAQ DSCI) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.